Bristol-Myers Squibb Company Securities Litigation (2018)

If you purchased a significant amount of shares of Bristol-Myers Squibb Company (NYSE: BMY) between January, 27th 2015 and October, 9th 2016, and/or if you purchased Bristol-Myers Squibb Company (NYSE: BMY) shares in January 2015 or earlier and currently hold any of those shares, you have certain options. Investors should register for updates.


Lawsuit Overview

Defendant:Bristol-Myers Squibb Company
Date Filed:February, 9th 2018
Sector:Health Care
Industry:Major Pharmaceuticals

According to the Complaint, Bristol-Myers purportedly discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products globally.

In January of 2015, the Company's CheckMate-026 study investigating the use of Opdivo (nivolumab) monotherapy as first-line therapy in patients with advanced non-small cell lung cancer ("NSCLC") was underway.

On August 5, 2016, the Company announced that its CheckMate-026 trial investigating the use of Opdivo (nivolumab) as monotherapy had failed because it did not meet its primary endpoint of progression-free survival.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that Bristol-Myers' CheckMate-026 trial was more likely to fail than Defendants were representing; (2) that BristolMyers' CheckMate-026 trial failed more severely than the Company indicated it did in the Company's August 5, 2016 announcements and disclosures; and (3) that, as a result of the foregoing, Defendants' statements about Bristol-Myers' business, operations, and prospects, were
materially false and/or misleading and/or lacked a reasonable basis.

Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Bristol-Myers Squibb Company

First Identified Complaint

Joseph Giugno, et al. v. Bristol-Myers Squibb Company, et al.

Date Filed:February, 9th 2018
Class Period Start:January, 27th 2015
Class Period End:October, 9th 2016
First Identified Complaint Filings
#Document TitleFiling Date